Novocure (NSDQ:NVCR) has inked a $150 million term loan agreement with Pharmakon Advisors’ investment fund, BioPharma Credit.
The St. Helier, N.J.-based company plans to set aside some of the new funds for working capital, as well as pay off its existing $100 million term loan debt.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure lands $150m term loan appeared first on MassDevice.